The FDA approves Boston Scientific’s (NYSE:BSX) next-generation Watchman FLX Left Atrial Appendage Closure (LAAC) device to reduce the risk of stroke in patients with non-valvular atrial fibrillation who need an alternative to oral blood thinners.
The left atrial appendage is where blood clots typically form in these patients.
Commercial launch will begin immediately.
The device was CE Mark’d in March 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.